Free Trial

enGene (ENGN) Competitors

enGene logo
$3.68 +0.07 (+1.94%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$3.70 +0.01 (+0.41%)
As of 08/15/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ENGN vs. NRIX, IMTX, MNMD, BGM, TNGX, QURE, DNA, STOK, TLRY, and PHAT

Should you be buying enGene stock or one of its competitors? The main competitors of enGene include Nurix Therapeutics (NRIX), Immatics (IMTX), Mind Medicine (MindMed) (MNMD), BGM Group (BGM), Tango Therapeutics (TNGX), uniQure (QURE), Ginkgo Bioworks (DNA), Stoke Therapeutics (STOK), Tilray Brands (TLRY), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical products" industry.

enGene vs. Its Competitors

Nurix Therapeutics (NASDAQ:NRIX) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

64.2% of enGene shares are held by institutional investors. 7.4% of Nurix Therapeutics shares are held by insiders. Comparatively, 10.4% of enGene shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, enGene had 10 more articles in the media than Nurix Therapeutics. MarketBeat recorded 12 mentions for enGene and 2 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.93 beat enGene's score of 0.25 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nurix Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
enGene
3 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral

enGene has lower revenue, but higher earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nurix Therapeutics$54.55M14.83-$193.57M-$2.61-4.05
enGeneN/AN/A-$55.14M-$1.65-2.23

enGene has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -234.57%. enGene's return on equity of -32.60% beat Nurix Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Nurix Therapeutics-234.57% -45.26% -34.71%
enGene N/A -32.60%-28.26%

Nurix Therapeutics presently has a consensus target price of $28.87, suggesting a potential upside of 172.84%. enGene has a consensus target price of $23.29, suggesting a potential upside of 532.76%. Given enGene's stronger consensus rating and higher probable upside, analysts clearly believe enGene is more favorable than Nurix Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nurix Therapeutics
0 Sell rating(s)
3 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.81
enGene
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.00

Nurix Therapeutics has a beta of 2.14, suggesting that its share price is 114% more volatile than the S&P 500. Comparatively, enGene has a beta of -0.41, suggesting that its share price is 141% less volatile than the S&P 500.

Summary

enGene beats Nurix Therapeutics on 12 of the 16 factors compared between the two stocks.

Get enGene News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENGN vs. The Competition

MetricenGeneMED IndustryMedical SectorNASDAQ Exchange
Market Cap$184.49M$3.09B$5.66B$9.82B
Dividend YieldN/A2.23%3.79%4.07%
P/E Ratio-2.2320.3830.5825.12
Price / SalesN/A356.76462.42114.82
Price / CashN/A42.3037.4059.05
Price / Book0.698.659.096.18
Net Income-$55.14M-$54.65M$3.25B$264.89M
7 Day PerformanceN/A6.58%7.32%4.18%
1 Month Performance1.66%7.54%5.41%1.99%
1 Year Performance-39.57%13.73%30.66%24.22%

enGene Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENGN
enGene
3.3331 of 5 stars
$3.68
+1.9%
$23.29
+532.8%
-37.6%$184.49MN/A-2.2331Short Interest ↓
NRIX
Nurix Therapeutics
2.592 of 5 stars
$9.65
-1.9%
$28.87
+199.1%
-52.3%$752.26M$54.55M-3.70300
IMTX
Immatics
2.2707 of 5 stars
$6.34
+2.6%
$14.67
+131.3%
-45.0%$751.18M$168.65M-37.29260News Coverage
Earnings Report
MNMD
Mind Medicine (MindMed)
2.4473 of 5 stars
$10.00
+1.5%
$24.71
+147.1%
+49.7%$749.47MN/A-6.5440
BGM
BGM Group
N/A$7.61
-1.2%
N/AN/A$748.61M$25.10M0.00298
TNGX
Tango Therapeutics
1.9418 of 5 stars
$6.41
-3.0%
$10.33
+61.2%
-28.0%$735.43M$42.07M-4.8290News Coverage
Positive News
Analyst Revision
QURE
uniQure
2.826 of 5 stars
$14.09
+6.1%
$36.55
+159.4%
+140.4%$728.63M$27.12M-3.59500Analyst Upgrade
DNA
Ginkgo Bioworks
0.9774 of 5 stars
$11.87
-3.5%
$8.50
-28.4%
N/A$719.36M$227.04M-2.02640
STOK
Stoke Therapeutics
4.142 of 5 stars
$13.16
+0.5%
$25.80
+96.0%
+27.8%$715.22M$36.56M16.66100Trending News
Earnings Report
Analyst Forecast
Insider Trade
Analyst Revision
TLRY
Tilray Brands
2.4037 of 5 stars
$0.92
+41.7%
$1.92
+108.6%
-47.2%$713.91M$821.31M-0.402,842Gap Up
High Trading Volume
PHAT
Phathom Pharmaceuticals
3.1264 of 5 stars
$10.28
+5.5%
$17.50
+70.2%
-21.9%$690.99M$55.25M-2.17110News Coverage

Related Companies and Tools


This page (NASDAQ:ENGN) was last updated on 8/16/2025 by MarketBeat.com Staff
From Our Partners